A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Latest Information Update: 30 May 2024
Price :
$35 *
At a glance
- Drugs Blinatumomab (Primary) ; Ibrutinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 28 May 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 28 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Feb 2025.
- 27 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Sep 2024.